

Francesco Crea

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4742836/francesco-crea-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

75
papers

2,196
citations

27
h-index

46
g-index

85
ext. papers

2,647
ext. citations

7.5
avg, IF

4.76
L-index

#	Paper	IF	Citations
75	A non-canonical role for pyruvate kinase M2 as a functional modulator of Ca signalling through IP receptors.. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2022 , 1869, 119206	4.9	1
74	Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response.. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022 , 41, 105	12.8	6
73	The long and short non-coding RNAs modulating EZH2 signaling in cancer.. <i>Journal of Hematology and Oncology</i> , 2022 , 15, 18	22.4	12
72	: an insight into lncRNA genetic evolution. <i>Epigenomics</i> , 2021 , 13, 1831-1843	4.4	3
71	The evolutionarily conserved long non-coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms. <i>Molecular Oncology</i> , 2021 , 15, 1921-1941	7.9	9
70	Long non-coding RNAs in the doxorubicin resistance of cancer cells. <i>Cancer Letters</i> , 2021 , 508, 104-114	9.9	42
69	Molecular events in neuroendocrine prostate cancer development. <i>Nature Reviews Urology</i> , 2021 , 18, 581-596	5.5	11
68	Age-related ultrastructural neurovascular changes in the female mouse cortex and hippocampus. <i>Neurobiology of Aging</i> , 2021 , 101, 273-284	5.6	5
67	The Long Non-Coding RNA H19 Drives the Proliferation of Diffuse Intrinsic Pontine Glioma with H3K27 Mutation. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
66	LncRNA promotes taxane resistance in castration-resistant prostate cancer via a BCL2A1-dependent mechanism. <i>Epigenomics</i> , 2020 , 12, 1123-1138	4.4	7
65	Long Non-coding RNAs and Cancer Cells Drug Resistance: An Unexpected Connection. <i>RNA Technologies</i> , 2020 , 167-198	0.2	1
64	EZH2 inhibition: a promising strategy to prevent cancer immune editing. <i>Epigenomics</i> , 2020 , 12, 1457-1476	4.4	12
63	The long noncoding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program. <i>Molecular Oncology</i> , 2019 , 13, 1121-1136	7.9	21
62	T-type calcium channels drive the proliferation of androgen-receptor negative prostate cancer cells. <i>Prostate</i> , 2019 , 79, 1580-1586	4.2	5
61	The role of histone lysine demethylases in cancer cells' resistance to tyrosine kinase inhibitors.. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019 , 2, 326-334	4.5	1
60	Treatment-emergent neuroendocrine prostate cancer: molecularly driven clinical guidelines. <i>International Journal of Endocrine Oncology</i> , 2019 , 6, IJE20	0.3	3
59	Heterochromatin Protein 1 Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer. <i>Cancer Research</i> , 2018 , 78, 2691-2704	10.1	31

58	Hypoxia and Noncoding RNAs in Taxane Resistance. <i>Trends in Pharmacological Sciences</i> , 2018 , 39, 695-709	3.2	16
57	Is HOTAIR really involved in neuroendocrine prostate cancer differentiation?. <i>Epigenomics</i> , 2018 , 10, 1259-1261	4.4	4
56	Elevated expression of a pharmacologic Polycomb signature predicts poor prognosis in gastric and breast cancer. <i>Epigenomics</i> , 2017 , 9, 1329-1335	4.4	5
55	miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer. <i>Scientific Reports</i> , 2017 , 7, 4079	4.9	25
54	EZH2 Single Nucleotide Variants (SNVs): Diagnostic and Prognostic Role in 10 Solid Tumor Types. <i>Epigenomes</i> , 2017 , 1, 18	2.3	1
53	Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation. <i>PLoS ONE</i> , 2017 , 12, e0182818	3.7	13
52	Biological and Clinical Evidence for Metabolic Dormancy in Solid Tumors Post Therapy. <i>Cancer Drug Discovery and Development</i> , 2017 , 17-29	0.3	1
51	Immuno-oncology of Dormant Tumours. <i>Cancer Drug Discovery and Development</i> , 2017 , 51-60	0.3	1
50	Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer. <i>Clinical Epigenetics</i> , 2016 , 8, 16	7.7	44
49	Integrated analysis of the prostate cancer small-nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression. <i>Molecular Oncology</i> , 2016 , 10, 693-703	7.9	33
48	The potential role of PHF6 as an oncogene: a genotranscriptomic/proteomic meta-analysis. <i>Tumor Biology</i> , 2016 , 37, 5317-25	2.9	6
47	Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients. <i>Oncology</i> , 2016 , 91, 283-288	3.6	1
46	The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer. <i>Epigenomics</i> , 2016 , 8, 721-31	4.4	80
45	The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo. <i>Molecular Cancer</i> , 2015 , 14, 46	42.1	59
44	Polycomb-mediated silencing in neuroendocrine prostate cancer. <i>Clinical Epigenetics</i> , 2015 , 7, 40	7.7	70
43	The epigenetic/noncoding origin of tumor dormancy. <i>Trends in Molecular Medicine</i> , 2015 , 21, 206-11	11.5	39
42	Polycomb genes are associated with response to imatinib in chronic myeloid leukemia. <i>Epigenomics</i> , 2015 , 7, 757-65	4.4	18
41	Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. <i>BMC Cancer</i> , 2015 , 15, 874	4.8	8

40	Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer. <i>Oncotarget</i> , 2015 , 6, 1806-20	3.3	33
39	The Non-Coding Transcriptome as a Dynamic Regulator of Prostate Cancer Metastasis. <i>FASEB Journal</i> , 2015 , 29, 221.3	0.9	
38	Genotranscriptomic meta-analysis of the Polycomb gene CBX2 in human cancers: initial evidence of an oncogenic role. <i>British Journal of Cancer</i> , 2014 , 111, 1663-72	8.7	48
37	The non-coding transcriptome as a dynamic regulator of cancer metastasis. <i>Cancer and Metastasis Reviews</i> , 2014 , 33, 1-16	9.6	74
36	Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. <i>Oncotarget</i> , 2014 , 5, 764-74	3.3	184
35	Histone modifications, stem cells and prostate cancer. <i>Current Pharmaceutical Design</i> , 2014 , 20, 1687-97	3.3	9
34	Histone lysine demethylases in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 86, 97-103	7	43
33	A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma. <i>Oncology Letters</i> , 2013 , 6, 1487-1491	2.6	10
32	Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. <i>International Journal of Molecular Sciences</i> , 2013 , 14, 7757-70	6.3	98
31	Mutational analysis of Polycomb genes in solid tumours identifies PHC3 amplification as a possible cancer-driving genetic alteration. <i>British Journal of Cancer</i> , 2013 , 109, 1699-702	8.7	10
30	Targeting Cancer Stem Cell Efficient DNA Repair Pathways: Screening for New Therapeutics 2013 , 157-172		
29	EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. <i>Cancer and Metastasis Reviews</i> , 2012 , 31, 753-61	9.6	131
28	The emerging role of histone lysine demethylases in prostate cancer. <i>Molecular Cancer</i> , 2012 , 11, 52	42.1	59
27	EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. <i>Annals of Oncology</i> , 2012 , 23, 1370-1371	10.3	7
26	An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2012 , 23, 1207-1213	10.3	36
25	Polycomb genes and cancer: time for clinical application?. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 83, 184-93	7	67
24	An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw. <i>Biomarkers in Medicine</i> , 2012 , 6, 201-9	2.3	24
23	Prognostic value of CD133 caused by mutant K-Ras and B-Raf--letter. <i>Clinical Cancer Research</i> , 2012 , 18, 4473; author reply 4474	12.9	

22	Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 1735-46	6.1	73
21	Evaluation of EZH2 SNPs in cholangiocarcinoma patients.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10611-10611		
20	Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. <i>Drug Resistance Updates</i> , 2011 , 14, 280-96	23.2	89
19	Pharmacogenomics and cancer stem cells: a changing landscape?. <i>Trends in Pharmacological Sciences</i> , 2011 , 32, 487-94	13.2	18
18	Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. <i>Molecular Cancer</i> , 2011 , 10, 40	42.1	131
17	BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer. <i>International Journal of Cancer</i> , 2011 , 128, 1946-54	7.5	67
16	Optical biosensors to analyze novel biomarkers in oncology. <i>Journal of Biophotonics</i> , 2011 , 4, 442-52	3.1	23
15	Transfection of a methylated promoter drives mesenchymal stem cell differentiation. <i>Epigenomics</i> , 2011 , 3, 11-2	4.4	
14	Faithful markers of circulating cancer stem cells: is CD133 sufficient for validation in clinics?. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3487-8; author reply 3488-90	2.2	12
13	Biological significance of DNA methylation patterns in human progenitor cells. <i>Epigenomics</i> , 2011 , 3, 12-3	4.4	1
12	Induced pluripotent stem cells derived from liver disease patients can differentiate into functional hepatocytes. <i>Epigenomics</i> , 2011 , 3, 13	4.4	
11	Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells. <i>Chemotherapy</i> , 2010 , 56, 303-12	3.2	18
10	Clinical significance of Polycomb gene expression in brain tumors. <i>Molecular Cancer</i> , 2010 , 9, 265	42.1	59
9	Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. <i>BMC Cancer</i> , 2010 , 10, 511	4.8	38
8	Pharmacogenetics of Angiogenesis 2010 , 233-242		
7	Cancer stem cell epigenetics and chemoresistance. <i>Epigenomics</i> , 2009 , 1, 63-79	4.4	58
6	Targeting prostate cancer stem cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2009 , 9, 1105-13	2.2	13
5	Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 1964-73	6.1	38

4	Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 72, 21-44	7	17
3	Pharmacogenomics in non-small-cell lung cancer chemotherapy. <i>Advanced Drug Delivery Reviews</i> , 2009 , 61, 408-17	18.5	24
2	Epigenetic gene regulation in stem cells and correlation to cancer. <i>Differentiation</i> , 2009 , 78, 1-17	3.5	63
1	Pharmacogenetics in oncology. <i>European Journal of Cancer, Supplement</i> , 2008 , 6, 74-78	1.6	0